	US 12,220,454 B2
	Adenoviral vector system for gene delivery
Suresh Kumar Mittal, West Lafayette, IN (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US)
Filed by Purdue Research Foundation, West Lafayette, IN (US)
Filed on Mar. 12, 2021, as Appl. No. 17/199,972.
Application 17/199,972 is a division of application No. 16/359,973, filed on Mar. 20, 2019, granted, now 10,968,464.
Claims priority of provisional application 62/646,936, filed on Mar. 23, 2018.
Prior Publication US 2022/0288188 A1, Sep. 15, 2022
Int. Cl. A61K 39/145 (2006.01); A61P 31/16 (2006.01); A61P 37/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/145 (2013.01) [A61P 31/16 (2018.01); A61P 37/04 (2018.01); A61K 2039/5256 (2013.01); C12N 2710/10334 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10352 (2013.01); C12N 2710/10371 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16171 (2013.01)]

18 Claims

1. A method of generating immunogenicity against a virus in a subject, comprising administering to said subject an effective amount of BAdV3 vaccine expressing an antigen of said virus, wherein said BAdV3 vaccine is produced in a bovine cell line co-transfected with:

a. a human adenovirus (HAdV) E1 region;

b. a bovine adenovirus E1BL gene; and

c. a bovine adenovirus type 3 (BAdV3) vector with E1A, E1BS, E1BL and E3 regions replaced by a gene expressing an antigen of said virus.